Last reviewed 2026-04-20 · How we verify

Ebov Mab114 (ANSUVIMAB)

Ansuvimab works by binding to the Ebola virus glycoprotein, preventing the virus from entering host cells.

Ansuvimab (Ebov-Mab114) is a Zaire Ebolavirus Glycoprotein-directed Antibody developed by Ridgeback Biotherapeutics. It is a monoclonal antibody that targets the Ebola virus, providing treatment for Ebola virus disease. Ansuvimab was FDA-approved in 2020 and is currently owned by Ridgeback Biotherapeutics. The commercial status of Ansuvimab is patented, and its safety considerations include potential allergic reactions and infusion-related side effects. Ansuvimab is a critical treatment option for patients with Ebola virus disease.

At a glance

Mechanism of action

Imagine the Ebola virus as a key that unlocks a door to enter a cell. Ansuvimab is like a lock that prevents the key from turning, stopping the virus from entering the cell and causing infection.

Approved indications

• Ebola virus disease

Common side effects

• Pyrexia
• Tachycardia
• Hypotension
• Diarrhea
• Vomiting
• Tachypnea
• Chills
• Hypoxia
• Abdominal pain
• Potassium, high (≥ 6.5 mmol/L)
• Sodium, low (< 125 mmol/L)
• Sodium, high (≥ 154 mmol/L)

Serious adverse events

• Infusion-related adverse events

Key clinical trials

• Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP
• Prophylaxis Vaccine Antibodies Ebola (PHASE2)
• Investigational Therapeutics for the Treatment of People With Ebola Virus Disease (PHASE2,PHASE3)
• Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.